Kanegafuchi Kagaku Kogyo Kabushiki Kaisha

Kaneka Corporation

Tetsu Kakutani

Kenji Yamashita

Kiyoshi Watanabe

Hajime Kawaharada

Hideo Niwa

Takaaki Ohara

Keiji Matsumoto

Kazuyoshi Yajima

Yasuhiro Ikenaka

Fumio Osakada

Takashi Asahi

Takeshi Fukuchi

Kaku Nakagawa

Hiroyuki Maruyama

Tetsuya Nagaoka

Hitoshi Yahara

Seishi Kyoizumi

Yasuhiro Inenaka

Tadahiro Edamura

Shinichi Yokota

Katsuhiro Shinjo

It is an object to utilize a novel HSCA-3 antigen occurring in immature hemopoietic stem cells and a monoclonal antibody recognizing said antigen in 1) the immunoassay or flow cytometry involving antibody labeling and 2) the isolation and purification of immature hemopoietic stem cells from human bone marrow cells, umbilical code blood or blood enriched in human hemopoietic stem cells by mobilization with G-CSF. It is directed to a novel HSCA-3 antigen occurring in immature hemopoietic stem cells and to a monoclonal antibody or an immunoreactive fragment thereof which recognizes said antigen.

Monoclonal antibody, its immunoreactive fragment and hybridoma

A sheep LFA-3 protein and derivertires thereof, and derivertives of a human LFA-3 protein, gene coding for the proteins, and processes for preparing the proteins. Said proteins have high affinity for human T-cells.

Cell adhesion protein, gene coding for the same, process for preparing

A TPA variant with replacement of amino acids is provided. In a typical embodiment, the variant has an amino acid sequence with replacement of the amino acid group consisting of asparagine at the 37th position, serine at the 38th position, glycine at the 39th position, arginine at the 40th position, alanine at the 41st position, and glutamine at the 42nd position from the N-terminus of the amino acid sequence of mature human tissue plasminogen activator.

Human plasminogen activator variants having amino acids 37-42

A chromosomal DNA sequence which codes for human lymphotoxin, a lymphotoxin expression vector which contains a DNA sequence wherein a chromosomal DNA sequence coding for human lymphotoxin and promoter region which functions in animal cell are linked together, lymphotoxin resistant cell line, transformed animal cell culture which is formed by transforming cultured animal cell with a lymphotoxin expression vector which contains a chromosomal DNA sequence coding for human lymphotoxin and, a process for preparing human lymphotoxin, which comprises transforming cultured animal cell with a lymphotoxin expression vector which contains a chromosomal DNA sequence coding for human lymphotoxin, culturing the transformed cell culture to produce human lymphotoxin, and collecting the human lymphotoxin. According to the present invention, LT which is expected for application as the antitumor agent can be produced effectively in a large amount.

Lymphotoxin DNA, lymphotoxin expression vector

A DNA sequence on which a chromosomal DNA sequence coding for human interferon-.gamma. (HuIFN-.gamma.) and having a TATA box is ligated to a sequence of a promoter. Cell cultures transformed with said DNA revealed a higher expression of HuIFN- than cell cultures transformed with a DNA which does not have such TATA box. When transformed with said DNA, cell cultures produced HuIFN-.gamma. in a serum free medium. Transformed cell cultures derived from blood cells of HuIFN-.gamma. resistant human cell-line also could produce HuIFN-.gamma..

Human interferon-gamma

Growing community of inventors

Kakogawa, Japan

Tetsu Kakutani